Reports Q3 revenue $159,000, consensus $3.28M. “Silence continues to focus on operational execution, highlighted by the rapid achievement of full enrollment in our ongoing SANRECO Phase 2 study of divesiran, our first-in-class siRNA for PV,” said Craig Tooman, President and Chief Executive Officer at Silence. “We believe the positive momentum in our divesiran PV program, combined with exciting advancements in our early-stage pipeline, positions us well for both near and long-term value creation. We are looking forward to a strong finish to the year and meaningful pipeline catalysts ahead in 2026.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN:
- Silence Therapeutics Completes Enrollment for Phase 2 Study
- Silence Therapeutics completes patient enrollment in SANRECO
- Silence Therapeutics: Promising mRNAi GOLD Platform and Strategic Initiatives Drive Buy Rating
- Silence Therapeutics: Strong Growth Potential with Promising Clinical Advances and Strategic Collaborations